Advanced search
Publication Cover
Immunotherapy Volume 3, 2011 - Issue 2
Submit an article Journal homepage
521
Views
0
CrossRef citations to date
0
Altmetric
Review

Antibody–Enzyme Fusion Proteins for Cancer Therapy

Carima Andrady1 Cancer Research UK Targeting & Imaging Group, Department of Oncology, UCL Cancer Institute, Paul O‘Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UKCorrespondence[email protected]
View further author information
,
Surinder K Sharma1 Cancer Research UK Targeting & Imaging Group, Department of Oncology, UCL Cancer Institute, Paul O‘Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UKView further author information
&
Kerry A Chester1 Cancer Research UK Targeting & Imaging Group, Department of Oncology, UCL Cancer Institute, Paul O‘Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UKView further author information
Pages 193-211 | Published online: 15 Feb 2011

Bibliography

  • Bagshawe KD : Antibody directed enzymes revive anti-cancer prodrugs concept.Br. J. Cancer56(5) , 531–532 (1987).
  • Bagshawe KD , SpringerCJ, SearleF et al.: A cytotoxic agent can be generated selectively at cancer sites.Br. J. Cancer58(6) , 700–703 (1988).
  • Senter PD , SaulnierMG, SchreiberGJ et al.: Antitumor effects of antibody–alkaline phosphatase conjugates in combination with etoposide phosphate.Proc. Natl Acad. Sci. USA85(13) , 4842–4846 (1988).
  • Bagshawe KD : Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.Expert Rev. Anticancer Ther.6(10) , 1421–1431 (2006).
  • Bagshawe KD : Targeting: the ADEPT story so far.Curr. Drug Targets10(2) , 152–157 (2009).
  • Senter PD , SpringerCJ: Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates.Adv. Drug Deliv. Rev.53(3) , 247–264 (2001).
  • Wallace PM , MacMasterJF, SmithVF, KerrDE, SenterPD, CosandWL: Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.Cancer Res.54(10) , 2719–2723 (1994).
  • Deckert PM , RennerC, CohenLS et al.: A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme–prodrug therapy.Br. J. Cancer88(6) , 937–939 (2003).
  • Kievit E , BershadE, NgE et al.: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.Cancer Res.59(7) , 1417–1421 (1999).
  • Coelho V , DerneddeJ, PetrauschU et al.: Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.Int. J. Oncol.31(4) , 951–957 (2007).
  • Panjideh H , Da Silva Coelho V, Dernedde J et al.: Biodistribution and efficacy of 131IA33scFv::CDy, a recombinant antibody–enzyme protein for colon cancer. Int. J. Oncol.32(4) , 925–930 (2008).
  • Goshorn SC , SvenssonHP, KerrDE, SomervilleJE, SenterPD, FellHP: Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to β-lactamase.Cancer Res.53(9) , 2123–2127 (1993).
  • Rodrigues ML , PrestaLG, KottsCE et al.: Development of a humanized disulfide-stabilized anti-p185HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.Cancer Res.55(1) , 63–70 (1995).
  • Siemers NO , KerrDE, YarnoldS et al.: Construction, expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.Bioconjug. Chem.8(4) , 510–519 (1997).
  • Kerr DE , VrudhulaVM, SvenssonHP, SiemersNO, SenterPD: Comparison of recombinant and synthetically formed monoclonal antibody-β-lactamase conjugates for anticancer prodrug activation.Bioconjug. Chem.10(6) , 1084–1089 (1999).
  • Vrudhula VM , KerrDE, SiemersNO, DubowchikGM, SenterPD: Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-β-lactamase fusion protein.Bioorg. Med. Chem. Lett.13(3) , 539–542 (2003).
  • Cortez-Retamozo V , BackmannN, SenterPD et al.: Efficient cancer therapy with a nanobody-based conjugate.Cancer Res.64(8) , 2853–2857 (2004).
  • Alderson RF , TokiBE, RobergeM et al.: Characterization of a CC49-based single-chain fragment-β-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).Bioconjug. Chem.17(2) , 410–418 (2006).
  • Phelan RM , OstermeierM, TownsendCA: Design and synthesis of a β-lactamase activated 5-fluorouracil prodrug.Bioorg. Med. Chem. Lett.19(4) , 1261–1263 (2009).
  • Shukla GS , KragDN: Developing bifunctional β-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter cloacae P99 cephalosporinase loops suitable for randomization and phage-display selection.J. Mol. Recog.22(6) , 425–436 (2009).
  • Lindner HA , LuninVV, AlaryA, HeckerR, CyglerM, MenardR: Essential roles of zinc ligation and enzyme dimerization for catalysis in the aminoacylase-1/M20 family.J. Biol. Chem.278(45) , 44496–44504 (2003).
  • Buchen S , NgampoloD, MeltonRG et al.: Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.Br. J. Cancer92(3) , 480–487 (2005).
  • Tuffaha HW , OmarSA: Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.J. Oncol. Pharm.Pract. DOI: 10.1177/1078155209348720 (2009) (Epub ahead of print).
  • Springer CJ , PoonGK, SharmaSK, BagshaweKD: Analysis of antibody–enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.Cell Biophys.24–25 , 193–207 (1994).
  • Springer CJ , DowellR, BurkePJ et al.: Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).J. Med. Chem.38(26) , 5051–5065 (1995).
  • Sharma SK , BagshaweKD, BurkePJ et al.: Galactosylated antibodies and antibody–enzyme conjugates in antibody-directed enzyme prodrug therapy.Cancer73(Suppl. 3) , 1114–1120 (1994).
  • Napier MP , SharmaSK, SpringerCJ et al.: Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.Clin. Cancer Res.6(3) , 765–772 (2000).
  • Michael NP , ChesterKA, MeltonRG et al.: In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein.Immunotechnology2(1) , 47–57 (1996).
  • Bhatia J , SharmaSK, ChesterKA et al.: Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.Int. J. Cancer85(4) , 571–577 (2000).
  • Medzihradszky KF , SpencerDI, SharmaSK et al.: Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody–enzyme fusion protein.Glycobiology14(1) , 27–37 (2004).
  • Sharma SK , PedleyRB, BhatiaJ et al.: Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.Clin. Cancer Res.11(2) , 814–825 (2005).
  • Kogelberg H , TolnerB, SharmaSK et al.: Clearance mechanism of a mannosylated antibody–enzyme fusion protein used in experimental cancer therapy.Glycobiology17(1) , 36–45 (2007).
  • Tolner B , SmithL, BegentRH, ChesterKA: Production of recombinant protein in Pichia pastoris by fermentation.Nat. Protoc.1(2) , 1006–1021 (2006).
  • Tolner B , SmithL, BegentRH, ChesterKA: Expanded-bed adsorption immobilized-metal affinity chromatography.Nat. Protoc.1(3) , 1213–1222 (2006).
  • Tolner B , SmithL, HillyerT et al.: From laboratory to Phase I/II cancer trials with recombinant biotherapeutics.Eur. J. Cancer43(17) , 2515–2522 (2007).
  • Mayer A , FrancisRJ, SharmaSK et al.: A Phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody–enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.Clin. Cancer Res.12(21) , 6509–6516 (2006).
  • Ackerman ME , PawlowskiD, WittrupKD: Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.Mol. Cancer Ther.7(7) , 2233–2240 (2008).
  • Bhatia J , SharmaSK, ChesterKA et al.: Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.Int. J. Cancer85(4) , 571–577 (2000).
  • Thurber GM , SchmidtMM, WittrupKD: Factors determining antibody distribution in tumors.Trends Pharmacol. Sci.29(2) , 57–61 (2008).
  • Thurber GM , SchmidtMM, WittrupKD: Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.Adv. Drug Deliv. Rev.60(12) , 1421–1434 (2008).
  • Bagshawe KD , SharmaSK: Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT.Transplant. Proc.28(6) , 3156–3158 (1996).
  • Bagshawe KD : Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application.Mol. Med. Today1(9) , 424–431 (1995).
  • Jevsevar S , KunsteljM, PorekarVG: PEGylation of therapeutic proteins.Biotechnol. J.5(1) , 113–128 (2010).
  • Nagata S , PastanI: Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.Adv. Drug Deliv. Rev.61(11) , 977–985 (2009).
  • Chester KA , BakerM, MayerA: Overcoming the immunologic response to foreign enzymes in cancer therapy.Exp. Rev. Clin. Immunol.1(4) , 549–559 (2005).
  • Spencer DI , RobsonL, PurdyD et al.: A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics.Proteomics2(3) , 271–279 (2002).
  • Mayer A , SharmaSK, TolnerB et al.: Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT).Br. J. Cancer90(12) , 2402–2410 (2004).
  • Weber CA , MehtaPJ, ArditoM, MoiseL, MartinB, De Groot AS: T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv. Drug Deliv. Rev.61(11) , 965–976 (2009).
  • De Groot AS , KnoppPM, MartinW: Deimmunization of therapeutic proteins by T-cell epitope modification.Dev. Biol. (Basel)122 , 171–194 (2005).
  • De Groot AS : Immunomics: discovering new targets for vaccines and therapeutics.Drug Discov. Today11(5–6) , 203–209 (2006).
  • De Groot AS , MartinW: Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics.Clin. Immunol.131(2) , 189–201 (2009).
  • Harding FA , LiuAD, SticklerM et al.: A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy.Mol. Cancer Ther.4(11) , 1791–1800 (2005).
  • Bosslet K , CzechJ, HoffmannD: Tumor-selective prodrug activation by fusion protein-mediated catalysis.Cancer Res.54(8) , 2151–2159 (1994).
  • Haisma HJ , SerneeMF, HooijbergE et al.: Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human β-glucuronidase for antibody-directed enzyme prodrug therapy.Blood92(1) , 184–190 (1998).
  • De Graaf M , BovenE, OosterhoffD et al.: A fully human anti-Ep-CAM scFv-β-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.Br. J. Cancer86(5) , 811–818 (2002).
  • Biela BH , KhawliLA, HuP, EpsteinAL: Chimeric TNT-3/human β-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).Cancer Biother. Radiopharm.18(3) , 339–353 (2003).
  • Hao XK , LiuJY, YueQH, WuGJ, BaiYJ, YinY: In vitro and in vivo prodrug therapy of prostate cancer using anti-γ-Sm-scFv/hCPA fusion protein.Prostate66(8) , 858–866 (2006).
  • Afshar S , AsaiT, MorrisonSL: Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.Mol. Cancer Ther.8(1) , 185–193 (2009).
  • Lowe H , TolnerB, KogelbergH et al.: A novel mutated human enzyme with a bis-chloro-phenol prodrug for antibody directed enzyme prodrug therapy (ADEPT). Presented at: The National Cancer Research Institute (NCRI) Cancer Conference 2007. Birmingham, UK, 30 September–3 October 2007.
  • Graff CP , ChesterK, BegentR, WittrupKD: Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C.Protein Eng. Des. Sel.17(4) , 293–304 (2004).
  • Pollack SJ , JacobsJW, SchultzPG: Selective chemical catalysis by an antibody.Science234(4783) , 1570–1573 (1986).
  • Tramontano A , JandaKD, LernerRA: Catalytic antibodies.Science234(4783) , 1566–1570 (1986).
  • Nevinsky GA , BunevaVN: Peculiarities of abzymes from sera and milk of healthy donors and patients with autoimmune and viral diseases.Biochemistry74(9) , 945–961 (2009).
  • Xu Y , YamamotoN, JandaKD: Catalytic antibodies: hapten design strategies and screening methods.Bioorg. Med. Chem.12(20) , 5247–5268 (2004).
  • Ikhmyangan EN , VasilenkoNL, BunevaVN, NevinskyGA: IgG antibodies with peroxidase-like activity from the sera of healthy Wistar rats.FEBS Lett.579(18) , 3960–3964 (2005).
  • Belogurov AJ , KozyrA, PonomarenkoN, GabibovA: Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde.Bioessays31(11) , 1161–1171 (2009).
  • Abraham S , GuoF, LiLS et al.: Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.Proc. Natl Acad. Sci. USA104(13) , 5584–5589 (2007).
  • Shabat D , LodeHN, PertlU et al.: In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy.Proc. Natl Acad. Sci. USA98(13) , 7528–7533 (2001).
  • Wojcik T , Kiec-KononowiczK: Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies.Curr. Med. Chem.15 , 1606–1615 (2008).
  • Huo R , WeiJ, XuJ et al.: Human catalytic antibody Se-scFv-B3 with high glutathione peroxidase activity.J. Mol. Recognit.21(5) , 324–329 (2008).
  • Xu J , SongJ, YanF et al.: Improving GPX activity of selenium-containing human single-chain Fv antibody by site-directed mutation based on the structural analysis.J. Mol. Recognit.22(4) , 293–300 (2009).
  • Nieva J , Wentworth Jr P: The antibody-catalyzed water oxidation pathway – a new chemical arm to immune defense? Trends Biochem. Sci.29(5) , 274–278 (2004).
  • Smith BM : Catalytic methods for the destruction of chemical warfare agents under ambient conditions.Chem. Soc. Rev.37(3) , 470–478 (2008).
  • Xu Y , HixonMS, YamamotoN et al.: Antibody-catalyzed anaerobic destruction of methamphetamine.Proc. Natl Acad. Sci. USA104(10) , 3681–3686 (2007).
  • McKenzie KM , MeeJM, RogersCJ, HixonMS, KaufmannGF, JandaKD: Identification and characterization of single chain anti-cocaine catalytic antibodies.J. Mol. Biol.365(3) , 722–731 (2007).
  • Robertson MP , ScottWG: Biochemistry: designer enzymes.Nature448(7155) , 757–758 (2007).
  • Sapparapu G , PlanqueSA, NishiyamaY, FoungSK, PaulS: Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.J. Biol. Chem.284(36) , 24622–24633 (2009).
  • Phichith D , BunS, Padiolleau-LefevreS et al.: Mutational and inhibitory analysis of a catalytic antibody. Implication for drug discovery.Mol. Immunol.47(2–3) , 348–356 (2009).
  • Blakey DC , BurkePJ, DaviesDH et al.: ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.Cancer Res.56(14) , 3287–3292 (1996).
  • Monks NR , BlakeyDC, CurtinNJ, EastSJ, HeuzeA, NewellDR: Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.Br. J. Cancer85(5) , 764–771 (2001).
  • McHugh PJ , SpanswickVJ, HartleyJA: Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.Lancet Oncol.2(8) , 483–490 (2001).
  • Tietze LF , KrewerB: Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.Chem. Bio. Drug Des.74(3) , 205–211 (2009).
  • Rooseboom M , CommandeurJN, VermeulenNP: Enzyme-catalyzed activation of anticancer prodrugs.Pharmacol. Rev.56(1) , 53–102 (2004).
  • Rautio J , KumpulainenH, HeimbachT et al.: Prodrugs: design and clinical applications.Nat. Rev. Drug Discov.7(3) , 255–270 (2008).
  • Kim WC , LeeCH: The role of mammalian ribonucleases (RNases) in cancer.Biochim. Biophys. Acta1796(2) , 99–113 (2009).
  • Boix E , NoguesMV: Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence.Mol. Biosyst.3(5) , 317–335 (2007).
  • Schein CH : From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases.Nat. Biotech.15(6) , 529–536 (1997).
  • D‘Alessio G , Di Donato A, Mazzarella L, Piccoli R: Seminal RNases: importance of diversity. In: Ribonucleases: Structures and Functions. D‘Alessio G, Riordan JF (Eds). Academic Press Inc., MA, USA, 383–423 (1997).
  • Saxena SK , RybakSM, WinklerG et al.: Comparison of RNases and toxins upon injection into Xenopus oocytes.J. Biol. Chem.266(31) , 21208–21214 (1991).
  • Rybak SM , SaxenaSK, AckermanEJ, YouleRJ: Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins.J. Biol. Chem.266(31) , 21202–21207 (1991).
  • Ilinskaya ON , KoschinskiA, MitkevichVA et al.: Cytotoxicity of RNases is increased by cationization and counteracted by K(Ca) channels.Biochem. Biophys. Res. Commun.314(2) , 550–554 (2004).
  • Johnson RJ , McCoyJG, BingmanCA, Phillips Jr GN, Raines RT: Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J. Mol. Bio.368(2) , 434–449 (2007).
  • Futami J , YamadaH: Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery.Curr. Pharm. Biotechnol.9(3) , 180–184 (2008).
  • Fuchs SM , RutkoskiTJ, KungVM, GroeschlRT, RainesRT: Increasing the potency of a cytotoxin with an arginine graft.Protein Eng. Des. Sel.20(10) , 505–509 (2007).
  • Ilinskaya ON , KoschinskiA, ReppH et al.: RNase-induced apoptosis:Fate of calcium-activated potassium channels.Biochimie90(5) , 717–725 (2008).
  • Zhao H , ArdeltB, ArdeltW, ShogenK, DarzynkiewiczZ: The cytotoxic ribonuclease onconase targets RNA interference (siRNA).Cell Cycle7(20) , 3258–3261 (2008).
  • Iordanov MS , RyabininaOP, WongJ et al.: Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis.Cancer Res.60(7) , 1983–1994 (2000).
  • Spalletti-Cernia D , SorrentinoR, DiGS et al.: Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis.J. Clin. Endocrinol. Metab.88(6) , 2900–2907 (2003).
  • Sorrentino S , NaddeoM, RussoA, D‘AlessioG: Degradation of double-stranded RNA by human pancreatic ribonuclease: crucial role of noncatalytic basic amino acid residues.Biochemistry42(34) , 10182–10190 (2003).
  • Blaszczyk J , GanJ, TropeaJE, CourtDL, WaughDS, JiX: Noncatalytic assembly of ribonuclease III with double-stranded RNA.Structure12(3) , 457–466 (2004).
  • Alford S , PearsonJ, CaretteA, InghamR, HowardP: α-sarcin catalytic activity is not required for cytotoxicity.BMC Biochem.10(1) , 9 (2009).
  • Pastan I , HassanR, FitzGeraldDJ, KreitmanRJ: Immunotoxin treatment of cancer.Annu. Rev. Med.58(1) , 221–237 (2007).
  • Kreitman RJ : Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.BioDrugs23(1) , 1–13 (2009).
  • Potala S , SahooSK, VermaRS: Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.Drug Discov. Today13(17–18) , 807–815 (2008).
  • Foss F : Clinical experience with denileukin diftitox (ONTAK).Semin. Oncol.33(Suppl. 3) , 11–16 (2006).
  • Stirpe F , BattelliMG: Ribosome-inactivating proteins: progress and problems.Cell Mol. Life Sci.63(16) , 1850–1866 (2006).
  • Cao Y , MarksJD, MarksJW, CheungLH, KimS, RosenblumMG: Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.Cancer Res.69(23) , 8987–8995 (2009).
  • Rosenberg HF : RNase A ribonucleases and host defense: an evolving story.J. Leukoc. Biol.83(5) , 1079–1087 (2008).
  • Dickson KA , HaigisMC, RainesRT: Ribonuclease inhibitor: structure and function. In: Progress in Nucleic Acid Research and Molecular Biology. Kivie M (Ed.). Academic Press Inc., MA, USA, 349–374 (2005)
  • Rutkoski TJ , RainesRT: Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.Curr. Pharm. Biotechnol.9(3) , 185–189 (2008).
  • De Lorenzo C , Di Malta C, Cali G, Troise F, Nitsch L, D‘Alessio G: Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett.581(2) , 296–300 (2007).
  • Peracaula R , ClearyKR, LorenzoJ, de Llorens R, Frazier ML: Human pancreatic ribonuclease 1: expression and distribution in pancreatic adenocarcinoma. Cancer89(6) , 1252–1258 (2000).
  • Fernandez-Salas E , PeracaulaR, FrazierML, de Llorens R: Ribonucleases expressed by human pancreatic adenocarcinoma cell lines. Eur. J. Biochem.267(5) , 1484–1494 (2000).
  • Rybak SM , NewtonDL: Natural and engineered cytotoxic ribonucleases: therapeutic potential.Exp. Cell Res.253(2) , 325–335 (1999).
  • Zewe M , RybakSM, DubelS et al.: Cloning and cytotoxicity of a human pancreatic RNase immunofusion.Immunotechnology3(2) , 127–136 (1997).
  • Erickson HA , JundMD, PennellCA: Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.Protein Eng. Des. Sel.19(1) , 37–45 (2006).
  • De Lorenzo C , NigroA, PiccoliR, D‘AlessioG: A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells.FEBS Lett.516(1–3) , 208–212 (2002).
  • De Lorenzo C , ArcielloA, CozzolinoR et al.: A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.Cancer Res.64(14) , 4870–4874 (2004).
  • Leich F , StohrN, RietzA, Ulbrich-HofmannR, ArnoldU: Endocytotic internalization as a crucial factor for the cytotoxicity of ribonucleases.J. Biol. Chem.282(38) , 27640–27646 (2007).
  • Riccio G , BorrielloM, D‘AlessioG, De Lorenzo C: A novel human antitumor dimeric immunoRNase. J. Immunother.31(5) (2008).
  • De Lorenzo C , D‘AlessioG: Human anti-ErbB2 immunoagents – immunoRNases and compact antibodies.FEBS J.276(6) , 1527–1535 (2009).
  • Braschoss S , HirschB, DubelS, SteinH, DurkopH: New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo.Leuk. Lymphoma48(6) , 1179–1186 (2007).
  • Menzel C , SchirrmannT, KonthurZ, JostockT, DubelS: Human antibody RNase fusion protein targeting CD30+ lymphomas.Blood111(7) , 3830–3837 (2008).
  • Dickson KA , RainesRT: Silencing an inhibitor unleashes a cytotoxic enzyme.Biochemistry48(23) , 5051–5053 (2009).
  • Bosch M , BenitoA, RiboM, PuigT, BeaumelleB, VilanovaM: A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity.Biochemistry43(8) , 2167–2177 (2004).
  • Leland PA , StaniszewskiKE, KimBM, RainesRT: Endowing human pancreatic ribonuclease with toxicity for cancer cells.J. Biol. Chem.276(46) , 43095–43102 (2001).
  • Merlino A , AvellaG, DiGS et al.: Structural features for the mechanism of antitumor action of a dimeric human pancreatic ribonuclease variant.Protein Sci.18(1) , 50–57 (2009).
  • Vihinen P , KallioinenM, VuoristoMS et al.: Serum angiogenin levels predict treatment response in patients with stage IV melanoma.Clin. Exp. Metastasis24(7) , 567–574 (2007).
  • Tello-Montoliu A , PatelJV, LipGY: Angiogenin: a review of the pathophysiology and potential clinical applications.J. Thromb. Haemost.4(9) , 1864–1874 (2006).
  • Newton DL , XueY, OlsonKA, FettJW, RybakSM: Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.Biochemistry35(2) , 545–553 (1996).
  • Russo N , NobileV, Di Donato A, Riordan JF, Vallee BL: The C-terminal region of human angiogenin has a dual role in enzymatic activity. Proc. Natl Acad. Sci. USA93(8) , 3243–3247 (1996).
  • Krauss J , ArndtMA, VuBK, NewtonDL, RybakSM: Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.Br. J. Haematol.128(5) , 602–609 (2005).
  • Arndt MA , KraussJ, SchwarzenbacherR, VuBK, GreeneS, RybakSM: Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin‘s lymphoma.Int. J. Cancer107(5) , 822–829 (2003).
  • Arndt MAE , KraussJ, RybakSM: Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.FEBS Lett.578(3) , 257–261 (2004).
  • Arndt MA , KraussJ, VuBK, NewtonDL, RybakSM: A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells.J. Immunother.28(3) , 245–251 (2005).
  • Huhn M , SasseS, TurMK et al.: Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.Cancer Res.61(24) , 8737–8742 (2001).
  • Barth S , MattheyB, HuhnM, DiehlV, EngertA: CD30L-ETA: a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.Cytokines Cell Mol. Ther.5(2) , 69–78 (1999).
  • Stocker M , TurMK, SasseS, KrussmannA, BarthS, EngertA: Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.Protein Expr. Purif.28(2) , 211–219 (2003).
  • Rybak SM , HoogenboomHR, MeadeHM, RausJC, SchwartzD, YouleRJ: Humanization of immunotoxins.Proc. Natl Acad. Sci. USA89(8) , 3165–3169 (1992).
  • Newton DL , PollockD, DiTullioP et al.: Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice.J. Immunol. Methods231(1–2) , 159–167 (1999).
  • Lee JE , RainesRT: Cytotoxicity of bovine seminal ribonuclease: monomer versus dimer.Biochemistry44(48) , 15760–15767 (2005).
  • Leland PA , RainesRT: Cancer chemotherapy–ribonucleases to the rescue.Chem. Biol.8(5) , 405–413 (2001).
  • Ardelt W , ArdeltB, DarzynkiewiczZ: Ribonucleases as potential modalities in anticancer therapy.Eur. J. Pharmacol.625(1–3) , 181–189 (2009).
  • Makarov AA , KolchinskyA, IlinskayaON: Binase and other microbial RNases as potential anticancer agents.Bioessays30(8) , 781–790 (2008).
  • Hartley RW : Homology between prokaryotic and eukaryotic ribonucleases.J. Mol. Evol.15(4) , 355–358 (1980).
  • Hill C , DodsonG, HeinemannU et al.: The structural and sequence homology of a family of microbial ribonucleases.Trends Biochem. Sci.8(10) , 364–369 (1983).
  • Lacadena J , varez-GarciaE, Carreras-SangraN et al.: Fungal ribotoxins: molecular dissection of a family of natural killers.FEMS Microbiol. Rev.31(2) , 212–237 (2007).
  • Buckle AM , SchreiberG, FershtAR: Protein–protein recognition: crystal structural analysis of a barnase-barstar complex at 2.0-A resolution.Biochemistry33(30) , 8878–8889 (1994).
  • Prior TI , FitzGeraldDJ, PastanI: Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol.Biochemistry31(14) , 3555–3559 (1992).
  • Prior TI , KunwarS, PastanI: Studies on the activity of barnase toxins in vitro and in vivo.Bioconjug. Chem.7(1) , 23–29 (1996).
  • Edelweiss E , BalandinTG, IvanovaJL et al.: Barnase as a new therapeutic agent triggering apoptosis in human cancer cells.PLoS One3(6) , E2434 (2008).
  • Balandin T , EdelweissE, AndronovaN, TreshalinaE, SapozhnikovA, DeyevS: Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.Invest. New Drugs (2009).
  • Darzynkiewicz Z , CarterSP, MikulskiSM, ArdeltWJ, ShogenK: Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent.Cell Tissue Kinet.21(3) , 169–182 (1988).
  • Smith MR , NewtonDL, MikulskiSM, RybakSM: Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases.Exp. Cell Res.247(1) , 220–232 (1999).
  • Saxena SK , SirdeshmukhR, ArdeltW, MikulskiSM, ShogenK, YouleRJ: Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family.J. Biol. Chem.277(17) , 15142–15146 (2002).
  • Costanzi J , SidranskyD, NavonA, GoldsweigH: Ribonucleases as a novel proapoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.Cancer Inves.23(7) , 643–650 (2005).
  • Lee I : Ranpirnase (onconase), a cytotoxic amphibian ribonuclease, manipulates tumor physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin. Biol. Ther.8(6) , 813–827 (2008).
  • Mikulski SM , CostanziJJ, VogelzangNJ et al.: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.J. Clin. Oncol.20(1) , 274–281 (2002).
  • Newton DL , HansenHJ, LiuH et al.: Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.Crit. Rev. Oncol. Hematol.39(1–2) , 79–86 (2001).
  • Hursey M , NewtonDL, HansenHJ, RubyD, GoldenbergDM, RybakSM: Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.Leuk. Lymphoma43(5) , 953–959 (2002).
  • Chang CH , SapraP, VanamaSS, HansenHJ, HorakID, GoldenbergDM: Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.Blood106(13) , 4308–4314 (2005).
  • Krauss J , ArndtMAE, ZhuZ et al.: Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.Br. J. Cancer90(9) , 1863–1870 (2004).
  • Krauss J , ArndtMAE, VuBK, NewtonDL, SeeberS, RybakSM: Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.Biochem. Biophys. Res. Commun.331(2) , 595–602 (2005).
  • Youle RJ , D‘AlessioG. Antitumor Ribonucleases. In: Ribonucleases: Structures and Functions. D‘Alessio G, Riordan JF (Eds). Academic Press Inc., MA, USA, 491–514 (1997)
  • Matousek J , SoucekJ, SlavikT, TomanekM, LeeJE, RainesRT: Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease.Comp. Biochem. Physiol. C Toxicol. Pharmacol.136(4) , 343–356 (2003).
  • Spalletti-Cernia D , SorrentinoR, DiGS et al.: Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin.Br. J. Cancer90(1) , 270–277 (2004).
  • Sica F , DiFA, MerlinoA, MazzarellaL: Structure and stability of the noncovalent swapped dimer of bovine seminal ribonuclease: an enzyme tailored to evade ribonuclease protein inhibitor.J. Biol. Chem.279(35) , 36753–36760 (2004).
  • Merlino A , ErcoleC, PiconeD, PizzoE, MazzarellaL, SicaF: The buried diversity of bovine seminal ribonuclease: shape and cytotoxicity of the swapped noncovalent form of the enzyme.J. Mol. Biol.376(2) , 427–437 (2008).
  • Bracale A , Spalletti-CerniaD, MastronicolaM et al.: Essential stations in the intracellular pathway of cytotoxic bovine seminal ribonuclease.Biochem. J.362(Pt 3) , 553–560 (2002).
  • Bracale A , CastaldiF, NitschL, D‘AlessioG: A role for the intersubunit disulfides of seminal RNase in the mechanism of its antitumor action.Eur. J. Biochem.270(9) , 1980–1987 (2003).
  • Benito A , RiboM, VilanovaM: On the track of antitumour ribonucleases.Mol. Biosyst.1(4) , 294–302 (2005).
  • Ercole C , ColamarinoRA, PizzoE, FogolariF, SpadacciniR, PiconeD: Comparison of the structural and functional properties of RNase A and BS-RNase: a stepwise mutagenesis approach.Biopolymers91(12) , 1009–1017 (2009).
  • Deonarain MP , EpenetosAA: Design, characterization and antitumor cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.Br. J. Cancer77(4) , 537–546 (1998).
  • Mathew M , VermaRS: Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.Cancer Sci.100(8) , 1359–1365 (2009).
  • Rosenblum MG , BarthS: Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions.Curr. Pharm. Des.15(23) , 2676–2692 (2009).
  • Heusel JW , WesselschmidtRL, ShrestaS, RussellJH, LeyTJ: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells.Cell76(6) , 977–987 (1994).
  • Thomas DA , DuC, XuM, WangX, LeyTJ: DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis.Immunity12(6) , 621–632 (2000).
  • Talanian RV , YangX, TurbovJ et al.: Granule-mediated killing: pathways for granzyme B-initiated apoptosis.J. Exp. Med.186(8) , 1323–1331 (1997).
  • Heibein JA , GopingIS, BarryM et al.: Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members Bid and Bax.J. Exp. Med.192(10) , 1391–1402 (2000).
  • Trapani JA , JansDA, JansPJ, SmythMJ, BrowneKA, SuttonVR: Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent.J. Biol. Chem.273(43) , 27934–27938 (1998).
  • Dalken B , GiesubelU, KnauerSK, WelsWS: Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition.Cell Death Differ.13(4) , 576–585 (2005).
  • Zhao J , ZhangLH, JiaLT et al.: Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells.J. Biol. Chem.279(20) , 21343–21348 (2004).
  • Stahnke B , ThepenT, StockerM et al.: Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.Mol. Cancer Ther.7(9) , 2924–2932 (2008).
  • Liu Y , CheungLH, HittelmanWN, RosenblumMG: Targeted delivery of human proapoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents.Mol. Cancer Ther.2(12) , 1341–1350 (2003).
  • Liu Y , ZhangW, NiuT et al.: Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.Neoplasia8(2) , 125–135 (2006).
  • Godal R , KeilholzU, UharekL et al.: Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2.Blood107(8) , 3205–3211 (2006).
  • Xu YM , WangLF, JiaLT et al.: A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors.J. Immunol.173(1) , 61–67 (2004).
  • Wang LF , ZhouY, XuYM et al.: A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.Cancer Inves.27(7) , 774–780 (2009).
  • Woo EJ , KimYG, KimMS et al.: Structural mechanism for inactivation and activation of CAD/DFF40 in the apoptotic pathway.Mol. Cell14(4) , 531–539 (2004).
  • Newton DL , NichollsPJ, RybakSM, YouleRJ: Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv.J. Biol. Chem.269(43) , 26739–26745 (1994).
  • Newton DL , Rybak SM: Unique recombinant human ribonuclease and inhibition of Kaposi‘s sarcoma cell growth. J. Natl Cancer Inst.90(23) , 1787–1791 (1998).
  • Takashi M , MidoriK, HirokoT et al.: Growth inhibition of mammalian cells by eosinophil cationic protein.Eur. J. Biochem.269(1) , 307–316 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.